Abridge will license from Wiley Cochrane's clinical evidence for the Abridge Assistant, which provides context-aware clinical decision support across more than 300 U.S. health systems
San Francisco, CA and Hoboken, NJ - Nov. 16, 2026 - Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation and learning, and Abridge, the first AI-native clinician intelligence platform, today announced a partnership to bring Cochrane evidence into clinical decision support enabled by the Abridge Assistant.
Through the partnership, Wiley will license to Abridge the Cochrane Database of Systematic Reviews-the home of gold standard evidence syntheses, widely used to inform clinical guidelines worldwide-and Cochrane Clinical Answers-a curated collection of actionable clinical insights drawn from Cochrane reviews. That evidence will be integrated into responses within the Abridge Assistant, appearing as concise, cited summaries with full text accessible to Wiley subscribers.
Clinicians face complex decisions under time pressure, alongside other demands that contribute to burnout. Each patient's circumstances require them to search for relevant medical evidence and assess how it applies in real time. The Abridge Assistant helps by bringing context-aware clinical decision support into the conversation, drawing on the patient's chart, the clinical conversation, and trusted medical evidence to provide cited responses tailored to the patient.
"Trusted evidence becomes even more useful when it connects to the context of care," said Shiv Rao, CEO and co-founder of Abridge, and a practicing cardiologist. "Our partnership with Wiley brings Cochrane's rigorously vetted, up-to-date medical evidence directly into Abridge Assistant, helping clinicians connect medical knowledge with the questions that arise in their daily practice within the existing security and governance framework of their organizations."
"Our partnership with Abridge, a leading provider of AI for health systems, reflects the growing role Wiley's evidence plays in leading-edge healthcare AI tools. As these tools become part of everyday practice, clinicians deserve evidence behind them they can trust, verify, and stand behind," said Armughan Rafat, chief AI and data analytics officer for Wiley.
Under the agreement, Wiley will license Cochrane's library of nearly 10,000 systematic reviews and about 4,000 clinical answers to Abridge for use within the Assistant, adding to the other published evidence sources it already draws on inside the clinical encounter. Abridge is used across more than 300 U.S. health systems and will support more than 120 million patient encounters this year.
"Promoting evidence-informed health decision-making, and advocating for equitable health, is core to Cochrane's mission. AI is changing how people access evidence, and partnerships like this help ensure that trustworthy evidence stays at the center of it," said Karla Soares-Weiser, CEO of Cochrane.
The multi-year partnership covers the integration of Cochrane evidence into decision support within the Assistant for U.S. care-delivery organizations, and positions Wiley and Abridge to continue exploring ways to extend evidence-based content into clinical workflows.